These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 23285063)

  • 81. Immunogenicity and protective efficacy of recombinant M2e.Hsp70c (Hsp70(359-610)) fusion protein against influenza virus infection in mice.
    Attaran H; Nili H; Tebianian M
    Virol Sin; 2014 Aug; 29(4):218-27. PubMed ID: 25160757
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Development of a heat-stable and orally delivered recombinant M2e-expressing B. subtilis spore-based influenza vaccine.
    Zhao G; Miao Y; Guo Y; Qiu H; Sun S; Kou Z; Yu H; Li J; Chen Y; Jiang S; Du L; Zhou Y
    Hum Vaccin Immunother; 2014; 10(12):3649-58. PubMed ID: 25483702
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine.
    Tsybalova LM; Stepanova LA; Shuklina MA; Mardanova ES; Kotlyarov RY; Potapchuk MV; Petrov SA; Blokhina EA; Ravin NV
    PLoS One; 2018; 13(8):e0201429. PubMed ID: 30138320
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A candidate dual vaccine against influenza and noroviruses.
    Xia M; Tan M; Wei C; Zhong W; Wang L; McNeal M; Jiang X
    Vaccine; 2011 Oct; 29(44):7670-7. PubMed ID: 21839795
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Cross-protection against influenza virus infection by intranasal administration of nucleoprotein-based vaccine with compound 48/80 adjuvant.
    Zheng M; Liu F; Shen Y; Wang S; Xu W; Fang F; Sun B; Xie Z; Chen Z
    Hum Vaccin Immunother; 2015; 11(2):397-406. PubMed ID: 25607884
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Induction of heterosubtypic cross-protection against influenza by a whole inactivated virus vaccine: the role of viral membrane fusion activity.
    Budimir N; Huckriede A; Meijerhof T; Boon L; Gostick E; Price DA; Wilschut J; de Haan A
    PLoS One; 2012; 7(1):e30898. PubMed ID: 22303469
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Primary pulmonary cytotoxic T lymphocytes induced by immunization with a vaccinia virus recombinant expressing influenza A virus nucleoprotein peptide do not protect mice against challenge.
    Lawson CM; Bennink JR; Restifo NP; Yewdell JW; Murphy BR
    J Virol; 1994 Jun; 68(6):3505-11. PubMed ID: 7514677
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Cross Protection against Influenza A Virus by Yeast-Expressed Heterologous Tandem Repeat M2 Extracellular Proteins.
    Lee YN; Kim MC; Lee YT; Hwang HS; Lee J; Kim C; Kang SM
    PLoS One; 2015; 10(9):e0137822. PubMed ID: 26366729
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Immunization with influenza A NP-expressing vaccinia virus recombinant protects mice against experimental infection with human and avian influenza viruses.
    Altstein AD; Gitelman AK; Smirnov YA; Piskareva LM; Zakharova LG; Pashvykina GV; Shmarov MM; Zhirnov OP; Varich NP; Ilyinskii PO; Shneider AM
    Arch Virol; 2006 May; 151(5):921-31. PubMed ID: 16292596
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Virus-like particle vaccine conferred complete protection against a lethal influenza virus challenge.
    Galarza JM; Latham T; Cupo A
    Viral Immunol; 2005; 18(2):365-72. PubMed ID: 16035948
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Expression of Influenza M2e-NP Recombinant Fusion Protein in
    Tan MP; Mohamed Alitheen NB; Tan WS; Yap WB
    Vaccines (Basel); 2022 Dec; 10(12):. PubMed ID: 36560475
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Combination of conserved recombinant proteins (NP & 3M2e) formulated with Alum protected BALB/c mice against influenza A/PR8/H1N1 virus challenge.
    Forqani M; Hosseini SM; Farahmand B; Saleh M; Shokouhi H; Torabi A; Fotouhi F
    Biotechnol Lett; 2021 Nov; 43(11):2137-2147. PubMed ID: 34491470
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Influenza NP core and HA or M2e shell double-layered protein nanoparticles induce broad protection against divergent influenza A viruses.
    Ma Y; Wang Y; Dong C; Gonzalez GX; Song Y; Zhu W; Kim J; Wei L; Wang BZ
    Nanomedicine; 2022 Feb; 40():102479. PubMed ID: 34743020
    [TBL] [Abstract][Full Text] [Related]  

  • 94. M2e-Based Influenza Vaccines with Nucleoprotein: A Review.
    Tan MP; Tan WS; Mohamed Alitheen NB; Yap WB
    Vaccines (Basel); 2021 Jul; 9(7):. PubMed ID: 34358155
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Nanoparticles Carrying Conserved Regions of Influenza A Hemagglutinin, Nucleoprotein, and M2 Protein Elicit a Strong Humoral and T Cell Immune Response and Protect Animals from Infection.
    Zykova AA; Blokhina EA; Stepanova LA; Shuklina MA; Ozhereleva OO; Tsybalova LM; Kuprianov VV; Ravin NV
    Molecules; 2023 Sep; 28(18):. PubMed ID: 37764217
    [TBL] [Abstract][Full Text] [Related]  

  • 96. The protective effect of intranasal immunization with influenza virus recombinant adenovirus vaccine on mucosal and systemic immune response.
    Lian YB; Hu MJ; Guo TK; Yang YL; Zhang RR; Huang JS; Yu LJ; Shi CW; Yang GL; Huang HB; Jiang YL; Wang JZ; Cao X; Wang N; Zeng Y; Yang WT; Wang CF
    Int Immunopharmacol; 2024 Mar; 130():111710. PubMed ID: 38394888
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Reduced protection of RIPK3-deficient mice against influenza by matrix protein 2 ectodomain targeted active and passive vaccination strategies.
    Oltean T; Ibanez LI; Divert T; Ysenbaert T; Van Eeckhoutte H; Goossens V; Schotsaert M; Bracke K; Schepens B; Maelfait J; Takahashi N; Saelens X; Vandenabeele P
    Cell Death Dis; 2022 Mar; 13(3):280. PubMed ID: 35351865
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Reasonable permutation of M2e enhances the effect of universal influenza nanovaccine.
    Ding P; Zhang G; Chen Y; Liu H; Liu Y; Jia R; Wang Y; Li G; Wang A
    Int J Biol Macromol; 2021 Mar; 173():244-250. PubMed ID: 33485888
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Generation and Characterization of Universal Live-Attenuated Influenza Vaccine Candidates Containing Multiple M2e Epitopes.
    Kotomina T; Isakova-Sivak I; Kim KH; Park BR; Jung YJ; Lee Y; Mezhenskaya D; Matyushenko V; Kang SM; Rudenko L
    Vaccines (Basel); 2020 Nov; 8(4):. PubMed ID: 33153089
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Presenting Influenza A M2e Antigen on Recombinant Spores of Bacillus subtilis.
    Łęga T; Weiher P; Obuchowski M; Nidzworski D
    PLoS One; 2016; 11(11):e0167225. PubMed ID: 27902762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.